trading today, page-50

I was going to respond to this yesterday to say that the downside of PFS is that the better the treatment, the longer the lag to PFS - so we could be delayed. Today's announcement based on the unblinded data makes this a clear possibility.

Note, however, that it is not uncommon for trials to have lower outcome rates for a variety of reasons unconnected with treatment efficacy. For example, exclusion criteria may remove patients who are more likely to fail, or general treatment improves in both the experimental and control arms.